Amneal’s expansion, primarily through front-end acquisitions and partnerships with established local companies, has allowed the company to bring its quality generic products that exceed and/or meet regulatory standards around the world. Its international entities bring the same commitment to quality and reliability, which has made Amneal Pharmaceuticals a trusted name globally.
Amneal Pharmaceuticals entered the Australian pharmaceuticals market in 2014 leveraging the company’s proven strategy of growing purposefully and seeking out those partners and organizations best positioned to contribute to its success.
Australian Government health reforms have made an impact on sustainable profitability in pharmacy. Consistent with the Amneal philosophy of building holistic business partnerships with select partners, Amneal Australia provides a suite of products, offers and programs that bring value to its choice customers.
Established in 1997 and acquired by Amneal in 2014, Pharmagenus is one of the most trusted generic companies in the Spanish healthcare market. With a strong focus on quality and reliable supply, Pharmagenus has gained the trust and confidence of our patients, pharmacists and healthcare providers.
Its mission is to offer to its partners and patients new medicines, as well as value-added products developed and produced by Amneal and by its partners globally.
Creo Pharma Ltd., a marketer and distributor of generic pharmaceuticals in the United Kingdom , is focused on the commercial pharmaceutical arena, providing alternative brands and niche generics to fill open prescriptions; supplying specific unlicensed and “off-label” products direct-to-retail and hospital pharmacy; and providing an after-hours emergency service for the supply of critical medicine.
Amneal and Creo Pharma is a formidable and flexible team dedicated to providing unparalleled quality and service to its customers and suppliers. Access to the European market allows Amneal to expand its product pipeline and offer its customers an ever-expanding range of innovative medicines and specialty generics.
In 2014, Amneal purchased bioeq pharma GmbH to provide generic products for the German pharmaceutical market. Patients, pharmacists and physicians can expect the same quality, reliability and service that has helped shape Amneal’s reputation worldwide.
Amneal Ireland Limited is located on Cahir Road in Cashel, County Tipperary. The facility will be dedicated to the production of metered dose and dry powder inhalers (MDIs and DPIs), injectable products as well as biosimilars – all high-end specialty medications.
Amneal chose Cashel not only for its excellent existing infrastructure, but also for the quality of its local workforce, the enthusiastic support of government leaders, and a positive business environment. The company in turn brings to Cashel a proven track record of providing steady jobs, empowering employees to do their best work, and collaborating with the surrounding community to build a superb operation, aligned with Amneal’s core values.
If you are interested in a job with Amneal Ireland, please send your resume or CV to email@example.com.
The company’s expanding operations in India have been an integral part of the Amneal’s R&D and manufacturing capabilities and expertise. Its active pharmaceutical ingredient (API) operations allow complete vertical integration of Amneal’s product portfolio.
These facilities have the very latest infrastructure and are staffed with expert scientific teams developing complex chemistries, novel routes of synthesis and numerous classes of compounds that are in strictest adherence to U.S. FDA standards. As a result, Amneal enjoys the flexibility to support several first-to-market and first-to-file opportunities in which possible API scarcity or complexity might otherwise pose a barrier to entry.